Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
M

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and 2nd Line IO Treatment Options + TKI Resistance Mechanisms

By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman
By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman
206 views
November 12, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Lung
05:21

Management of ALK+ NSCLC Through First and Subsequent Lines of Thera…

Xth Eurasian Hematology-Oncology Congress

P. Yumuk

89 views
17:12

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy…

Xth Eurasian Hematology-Oncology Congress

P. Yumuk

170 views
20:50

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Trea…

Xth Eurasian Hematology-Oncology Congress

M. Erman

110 views
08:26

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and …

Xth Eurasian Hematology-Oncology Congress

M. Erman

206 views
05:02

Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

121 views
14:47
Xth Eurasian Hematology-Oncology Congress

(DO NOT USE) Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is …

Feat. B. Uluc
05:57

1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced NSCL…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

181 views